JP2020517239A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517239A5 JP2020517239A5 JP2019556600A JP2019556600A JP2020517239A5 JP 2020517239 A5 JP2020517239 A5 JP 2020517239A5 JP 2019556600 A JP2019556600 A JP 2019556600A JP 2019556600 A JP2019556600 A JP 2019556600A JP 2020517239 A5 JP2020517239 A5 JP 2020517239A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- antibody
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical class 0.000 claims 13
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 12
- 239000000427 antigen Substances 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 9
- 150000001413 amino acids Chemical group 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229960001153 serine Drugs 0.000 claims 2
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- 229930182821 L-proline Natural products 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 230000000112 colonic effect Effects 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 102000048776 human CD274 Human genes 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005264 laryngeal carcinoma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 229960002429 proline Drugs 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022178282A JP2023025003A (ja) | 2017-04-18 | 2022-11-07 | 抗ｐｄ－ｌ１抗体とその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| USPCT/US2017/028206 | 2017-04-18 | ||
| US2017028206 | 2017-04-18 | ||
| PCT/US2018/028206 WO2018195226A1 (en) | 2017-04-18 | 2018-04-18 | Anti-pd-l1 antibody and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022178282A Division JP2023025003A (ja) | 2017-04-18 | 2022-11-07 | 抗ｐｄ－ｌ１抗体とその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020517239A JP2020517239A (ja) | 2020-06-18 |
| JP2020517239A5 true JP2020517239A5 (enExample) | 2021-05-13 |
Family
ID=63856823
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556600A Pending JP2020517239A (ja) | 2017-04-18 | 2018-04-18 | 抗ｐｄ−ｌ１抗体とその使用 |
| JP2022178282A Pending JP2023025003A (ja) | 2017-04-18 | 2022-11-07 | 抗ｐｄ－ｌ１抗体とその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022178282A Pending JP2023025003A (ja) | 2017-04-18 | 2022-11-07 | 抗ｐｄ－ｌ１抗体とその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20210115143A1 (enExample) |
| EP (1) | EP3612565A4 (enExample) |
| JP (2) | JP2020517239A (enExample) |
| KR (1) | KR102323960B1 (enExample) |
| CN (1) | CN110856446A (enExample) |
| AU (1) | AU2018256392B2 (enExample) |
| BR (1) | BR112019021828B1 (enExample) |
| CA (1) | CA3059447A1 (enExample) |
| CL (1) | CL2019002953A1 (enExample) |
| CO (1) | CO2019012118A2 (enExample) |
| EA (1) | EA201900443A1 (enExample) |
| MA (1) | MA50038A (enExample) |
| MX (1) | MX2019012461A (enExample) |
| MY (1) | MY199319A (enExample) |
| PH (1) | PH12019502302A1 (enExample) |
| SG (1) | SG11201909041SA (enExample) |
| WO (1) | WO2018195226A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| BR112018076260A2 (pt) | 2016-06-20 | 2019-03-26 | Kymab Limited | anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina |
| US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
| MX2021005594A (es) * | 2018-11-13 | 2021-10-22 | Compass Therapeutics Llc | Constructos multiespecificos de union contra moleculas de puntos de control y usos de los mismos. |
| CN113646330A (zh) * | 2018-11-14 | 2021-11-12 | 鲁比克治疗股份有限公司 | 工程化cd25多肽及其用途 |
| JP7619941B2 (ja) | 2018-11-14 | 2025-01-22 | アイバイオ， インク． | Ｃｄ２５抗体 |
| CN109929037B (zh) | 2019-04-01 | 2023-03-17 | 华博生物医药技术（上海）有限公司 | 针对程序性死亡配体的结合物及其应用 |
| AU2020271467B2 (en) * | 2019-04-11 | 2024-06-27 | Scripps Korea Antibody Institute | Antibodies against programmed death-ligand 1 and uses thereof |
| US11208486B2 (en) * | 2019-04-26 | 2021-12-28 | I-Mab Biopharma Us Limited | Human PD-L1 antibodies |
| US20210403568A1 (en) * | 2020-06-29 | 2021-12-30 | Cai Gu Huang | Biopharmaceutical formulation of anti-pd-1, anti-pd-l1, and anti-vegfr therapeutic monoclonal antibodies and method for treating nsclc by inhalation |
| CA3187850A1 (en) * | 2020-08-04 | 2022-02-10 | Bryan Glaser | Pd-l1 binding agents and uses thereof |
| WO2023046113A1 (zh) * | 2021-09-24 | 2023-03-30 | 广东菲鹏制药股份有限公司 | 一种抗人pd-l1人源化抗体或其抗原结合片段及其应用 |
| EP4658310A1 (en) | 2023-01-30 | 2025-12-10 | Kymab Limited | Antibodies |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE454137T1 (de) * | 2001-07-25 | 2010-01-15 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
| WO2010077634A1 (en) * | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| US10202454B2 (en) * | 2013-10-25 | 2019-02-12 | Dana-Farber Cancer Institute, Inc. | Anti-PD-L1 monoclonal antibodies and fragments thereof |
| EP4070818A3 (en) * | 2014-01-06 | 2023-01-11 | The Trustees of the University of Pennsylvania | Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy |
| WO2015127288A1 (en) * | 2014-02-20 | 2015-08-27 | Alder Biopharmaceuticals, Inc. | Anti-acth antibodies and use thereof |
| CN105777906B (zh) * | 2014-12-19 | 2019-04-23 | 苏州丁孚靶点生物技术有限公司 | 抗pd-l1全人抗体及其应用 |
| MX2017011644A (es) * | 2015-03-13 | 2017-12-04 | Cytomx Therapeutics Inc | Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos. |
| RU2770590C2 (ru) * | 2016-10-30 | 2022-04-18 | Шанхай Хенлиус Байотек, Инк. | Антитела против pd-l1 и их варианты |
-
2018
- 2018-04-18 CA CA3059447A patent/CA3059447A1/en active Pending
- 2018-04-18 BR BR112019021828-9A patent/BR112019021828B1/pt active IP Right Grant
- 2018-04-18 MA MA050038A patent/MA50038A/fr unknown
- 2018-04-18 US US16/606,647 patent/US20210115143A1/en not_active Abandoned
- 2018-04-18 JP JP2019556600A patent/JP2020517239A/ja active Pending
- 2018-04-18 MX MX2019012461A patent/MX2019012461A/es unknown
- 2018-04-18 SG SG11201909041S patent/SG11201909041SA/en unknown
- 2018-04-18 WO PCT/US2018/028206 patent/WO2018195226A1/en not_active Ceased
- 2018-04-18 EA EA201900443A patent/EA201900443A1/ru unknown
- 2018-04-18 AU AU2018256392A patent/AU2018256392B2/en not_active Ceased
- 2018-04-18 KR KR1020197032419A patent/KR102323960B1/ko active Active
- 2018-04-18 CN CN201880025898.4A patent/CN110856446A/zh active Pending
- 2018-04-18 MY MYPI2019006142A patent/MY199319A/en unknown
- 2018-04-18 EP EP18788069.5A patent/EP3612565A4/en active Pending
-
2019
- 2019-10-07 PH PH12019502302A patent/PH12019502302A1/en unknown
- 2019-10-16 CL CL2019002953A patent/CL2019002953A1/es unknown
- 2019-10-29 CO CONC2019/0012118A patent/CO2019012118A2/es unknown
-
2022
- 2022-11-07 JP JP2022178282A patent/JP2023025003A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020517239A5 (enExample) | ||
| JP2019507135A5 (enExample) | ||
| CN110799539B (zh) | 抗4-1bb抗体及其制备和使用方法 | |
| JP2019501883A5 (enExample) | ||
| JP2019536430A5 (enExample) | ||
| JP2019502405A5 (enExample) | ||
| JP2021502104A5 (enExample) | ||
| JP2020501531A5 (enExample) | ||
| RU2018139339A (ru) | Новые биспецифические полипептиды против cd137 | |
| JP2017531028A5 (enExample) | ||
| JP2018512138A5 (enExample) | ||
| JP2009521496A5 (enExample) | ||
| JP2010531140A5 (enExample) | ||
| RU2009149205A (ru) | Моноклональные антитела против клаудина-18 для лечения рака | |
| JP2025069432A5 (enExample) | ||
| JP2010523096A5 (enExample) | ||
| JP2024119853A5 (enExample) | ||
| JP2007515165A5 (enExample) | ||
| JP2020502233A5 (enExample) | ||
| JP2020533965A5 (enExample) | ||
| JP2016518333A5 (enExample) | ||
| JP2020513759A5 (enExample) | ||
| JP2020531003A5 (enExample) | ||
| US20230340119A1 (en) | Composition of triax antibodies and method of making and using thereof | |
| JP2024020436A5 (enExample) |